Clinical Research Directory
Browse clinical research sites, groups, and studies.
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Summary
Stereotactic Ablative Radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment. This new technique can potentially allow radiation treatments to be focused more precisely, and delivered more accurately than with older treatments. This improvement could help by reducing side effects and by improving the chance of controlling the cancer by more precisely treating the cancer. The purpose of this study is to compare SABR with current approaches of chemotherapy and conventional radiotherapy to assess the impact on overall survival and quality of life.
Official title: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
99
Start Date
2011-11
Completion Date
2026-06
Last Updated
2023-10-05
Healthy Volunteers
No
Conditions
Interventions
Stereotactic ablative radiotherapy
Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
palliative radiotherapy
Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows: Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions Liver: 20 Gy in 5 fractions if standard institutional practice
Locations (10)
Alfred Health, William Burkland Radiotherapy Centre
Melbourne, Victoria, Australia
BC Cancer Agency
Vancouver, British Columbia, Canada
Atlantic Clinical Cancer Research , QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Juravinski Cancer Centre, Hamilton Health Sciences
Hamilton, Ontario, Canada
London Regional Cancer Program of the Lawson Health Research Institute
London, Ontario, Canada
Ottawa Cancer Centre
Ottawa, Ontario, Canada
PEI Cancer Treatment Center
Charlottetown, Prince Edward Island, Canada
McGill University Health Centre Research Institute
Montreal, Quebec, Canada
VU University Amsterdam (VUmc)
Amsterdam, Netherlands
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom